Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

Viagra – Melanoma MDL Might Include Cialis Lawsuits And Levitra Cases

October 19, 2016 By Law Offices of Thomas J. Lamb, P.A.

As regards drug injury lawsuits concerning the melanoma side effect of male erectile dysfunction (ED) pills, that litigation began with Viagra cases being filed against Pfizer, the drug company responsible for Viagra. By April 2016 there was a sufficient federal court Viagra lawsuits filed that the Judicial Panel on Multidistrict Litigation (JPML) … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cialis, Levitra, Melanoma, Viagra

Mesothelioma Treatment Center at Baylor St. Luke’s launches clinical trial for cancer patients

October 13, 2016 By Law Offices of Thomas J. Lamb, P.A.

The Baylor College of Medicine Mesothelioma Treatment Center at Baylor St. Luke’s Medical Center announced today that it has opened a new clinical trial that combines immunotherapy and surgery for the treatment of mesothelioma. This is the first in-human study of neoadjuvant (before surgery) administration of a checkpoint inhibitor immunotherapy … [Read more...]

Filed Under: Asbestos, Mesothelioma Tagged With: asbestos, asbestos cancer, mesothelioma, mesothelioma treatments

Risk of Hepatitis B Reactivation Associated With Gleevec And Iclusig

October 12, 2016 By Law Offices of Thomas J. Lamb, P.A.

Currently available medicines in the BCR-ABL TKIs class of drugs include Gleevec and Iclusig, as well as Tasigna, Bosulif, and Sprycel. These BCR-ABL tyrosine kinase inhibitors (TKIs) are used for the treatment of specific types of blood cancers, including Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) and Ph+ acute … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Bosulif, Gleevec, Hepatitis, Iclusig, Sprycel, Tasigna

Mesothelioma from asbestos exposures: Epidemiologic patterns and impact in the United States

October 10, 2016 By Law Offices of Thomas J. Lamb, P.A.

Mesothelioma, a rare tumor, is highly correlated with asbestos exposure. Mesothelioma, similar to all asbestos-related diseases, is dose/intensity dependent to some degree, and studies showed the risk of mesothelioma rises with cumulative exposures. Multiple processes occur in an individual before mesothelioma occurs. The impact of mesothelioma in … [Read more...]

Filed Under: Asbestos, Mesothelioma Tagged With: asbestos, asbestos cancer, asbestos exposure, asbestos-related disease, mesothelioma

Black-Box Warning For Harvoni, Sovaldi, Viekira Pak: Hepatitis B Risk

October 7, 2016 By Law Offices of Thomas J. Lamb, P.A.

Direct-acting antivirals (DAAs) are a class of prescription medicines that are FDA-approved to treat adults with hepatitis C virus (HCV) infection. These medicines are available as single-ingredient products and also in combination with other HCV medicines. Here is a list of direct-acting antivirals currently available in the US: Daklinza … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Daklinza, Epclusa, Harvoni, Hepatitis, Olysio, Sovaldi, Technivie, Viekira Pak, Zepatier

COA finds electrician can sue former employers for mesothelioma diagnosis

October 3, 2016 By Law Offices of Thomas J. Lamb, P.A.

The Indiana Court of Appeals held Wednesday that an electrician can sue his former employers for negligence and liability after he was exposed to asbestos. Larry Myers worked as an electrician for Koontz-Wagner Electric from 1961 to 1980, serving as an independent contract for companies such as Bremen Casting and Mastic Home Exteriors Inc. During … [Read more...]

Filed Under: Asbestos, Mesothelioma Tagged With: asbestos, asbestos exposure, asbestos lawsuits, mesothelioma, mesothelioma lawsuits

What’s in a Name? Debate on What to Call Novel Oral Anticoagulants

September 30, 2016 By Law Offices of Thomas J. Lamb, P.A.

Recently, controversy has arisen over what to call the novel oral anticoagulant class of drugs, which includes Pradaxa, Xarelto, Savaysa, and Eliquis.  The article "NOAC, DOAC, or TSOAC: What Should We Call Novel Oral Anticoagulants?" provides some interesting information about the different sides of this debate. Here is a list of the possible … [Read more...]

Filed Under: Unsafe Drugs Tagged With: anticoagulants, antidotes, bleeding events, blood thinners, DOAC, drug injury, Eliquis, FDA, Gastrointestinal (GI) Bleeds, hemorrhagic strokes, heparin, increased risks, intracranial hemorrhages, NOAC, ODI, Pradaxa, reversal agents, safety warnings, Savaysa, side effects, SODA, TSOAC, warfarin, Xarelto

September 2016 Savaysa Label Change Points Out There Is Still No Antidote

September 30, 2016 By Law Offices of Thomas J. Lamb, P.A.

Savaysa (edoxaban) is a factor Xa inhibitor which was approved by the FDA in 2015. Savaysa has the following so-called “indications” or approved uses: To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; and, For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following … [Read more...]

Filed Under: Unsafe Drugs Tagged With: bleeding risk, Savaysa

Adjuvant Chemotherapy Improves Survival in Diffuse Malignant Peritoneal Mesothelioma

September 29, 2016 By Law Offices of Thomas J. Lamb, P.A.

This retrospective study evaluated the effects of perioperative treatment options in 126 patients with diffuse malignant peritoneal mesothelioma (DMPM) undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). The 5-year overall survival was significantly different among the perioperative treatment groups: 40% in … [Read more...]

Filed Under: Asbestos, Mesothelioma Tagged With: asbestos, asbestos cancer, mesothelioma, mesothelioma treatments

FDA grants fast track designation to galinpepimut-S for malignant plural mesothelioma

September 26, 2016 By Law Offices of Thomas J. Lamb, P.A.

The FDA granted fast track designation to galinpepimut-S for the treatment of malignant pleural mesothelioma, according to the drug’s manufacturer. “This fast track designation underscores the importance of galinpepimut-S as a potential treatment option in mesothelioma … [We] expect the fast track designation to expedite the time to market, … [Read more...]

Filed Under: Asbestos, Mesothelioma Tagged With: asbestos cancer, mesothelioma, mesothelioma treatments

  • « Previous Page
  • 1
  • …
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.